Genentech Herceptin patent litigation
Executive Summary
Chiron lawsuit claims Genentech's HER-2 monoclonal antibody Herceptin infringes its recently issued patent No. 6,054,561, which covers monoclonal antibodies that bind selectively to the HER-2 antigen. Chiron said it would be "excited to license the technology, on commercially reasonable terms, to Genentech and others." The lawsuit, filed June 8 in Sacramento federal court, seeks treble damages but does not request an injunction on Genentech's marketing of the breast cancer therapy